The developed colon-targeted matrix tablet of ornidazole exhibited stability in terms of physical properties, drug content uniformity, and dissolution pattern after storage at 40°C for two months. These findings suggest that the formulated tablets have the potential for effective treatment of ulcerative colitis and Crohn's disease by delivering ornidazole directly to the colon. Further studies are warranted to assess the in vivo performance and therapeutic efficacy of the colon-targeted ornidazole matrix tablets.
No takes yet. Share an insight, caveat, or question.
- et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: